<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994161</url>
  </required_header>
  <id_info>
    <org_study_id>XW125-S003</org_study_id>
    <nct_id>NCT01994161</nct_id>
  </id_info>
  <brief_title>Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis(CRTICAS)</brief_title>
  <official_title>Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is an prospective, government-funded registration study that will observe the
      safety and effectiveness of intracranial stenting for preventing stroke during a mean
      follow-up of 12 months in patients with symptomatic stenosis of a major intracranial artery
      (MCA, carotid, vertebral, basilar). This trial will be launched by Xuanwu Hospital, Capital
      University of Medical Science, with 20 collaborators participating. Enrollment will begin in
      2013, and it aims to have a sample size of 840 subjects in 2 years. The trial is scheduled to
      complete in 2015.

      As we know, SAMMPRIS is flawed with defect in design, heterogeneity in experience and
      credentials of operators and high rate of complication; Whether the interventional therapy
      for symtomatic intracranial artery stenosis is effective or not remained resolved. This trial
      has been modified based on SAMMPRIS in order to acquire the data for China: Technique,
      experience, and credential of the operators are closely related with perioperative
      complications in PTAS. The investigators select 50 large-scale medical centers for
      participation on the basis of geographical distribution. All the participants are ranked as
      top in China. They have the most experienced surgeons or interventionist in China, and are
      fully qualified for this trial. This will guarantee the success and safety of technique,
      maintain the continuity of operator's experience, and make the complication rate as low as
      possible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title:Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic
      Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial

      Design of trial:

      This trial is an prospective, government-funded registration study that will observe the
      safety and effectiveness of intracranial stenting for preventing stroke during a mean
      follow-up of 3 years in patients with symptomatic stenosis of a major intracranial artery
      (MCA, carotid, vertebral, basilar). This trial was launched by Xuanwu Hospital, Capital
      University of Medical Science, with 40 collaborators participating. Enrollment will begin in
      2013, and it aims to have a sample size of 840 subjects in 2 years. The trial is scheduled to
      complete in 2015.

      Details:

      SAMMPRIS (Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in
      Intracranial Stenosis) hasn't received the expected results; But, it does not mean that
      angioplasty with stent on intracranial treatment come to a full stop. On the contrary, a
      discrepancy on reported data between multi-centre RCT and most single center studies urges us
      for thorough investigation in future.

      As we know, SAMMPRIS is flawed with defect in design, heterogeneity in experience and
      credentials of operators and high rate of complication; Some questions about SAMMPRIS have
      been raised, and remained unresolved.

      This trial has been modified based on SAMMPRIS in order to acquire the data for China:
      Technique, experience, and credential of the operators are closely related with perioperative
      complications in PTAS. The investigators select 40 large-scale medical centers for
      participation on the basis of geographical distribution. All the participants are ranked as
      top in China. They have the most experienced surgeons or interventionist in China, and are
      fully qualified for this trial. This will guarantee the success and safety of technique,
      maintain the continuity of operator's experience, and make the complication rate as low as
      possible.

      SAMMPRIS was stopped ahead of schedule due to the safety concern. More than half of the PTAS
      patients were lost for follow-up at 1 year, and the remaining were followed up with a mean
      duration less than 1 year. It leaves the question of long-time follow-up data open. Base on
      SAMMPRIS, the investigators' trial will conduct a systematic follow-up system. Upon
      recruitment, all the patients' neurological and imaging examination will be determined at
      baseline, 1 week, 1 month, 6 months , 12 months after surgery, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Ischemic stroke, death or cardiovascular events</measure>
    <time_frame>30 days</time_frame>
    <description>The participants who suffer from Ischemic stroke, death or cardiovascular events after enrollment or any revascularization procedure of the qualifying lesion in the territory of the symptomatic intracranial artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any stroke, or death</measure>
    <time_frame>beyond 30 days through 6 months</time_frame>
    <description>the number of participants who suffer from any stroke(minor or major, ischemic or bleeding) or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of participants who suffer from restenosis (&gt;50%) related to intracranial stenting</measure>
    <time_frame>up to 12 months</time_frame>
    <description>the number of participants who suffer from restenosis (&gt;50%) related to intracranial stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes from baseline in mRS, national institutes of health stroke scale (NIHSS) and Barthel Index</measure>
    <time_frame>at 7 days, 30 days, 6 months, 12 months, 24 months and 36 months</time_frame>
    <description>the changes from baseline in mRS, national institutes of health stroke scale (NIHSS) and Barthel Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of participants who survives in all patients</measure>
    <time_frame>beyond 12 months to 36 months</time_frame>
    <description>the number of participants who survives in all patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intracranial stenting group</arm_group_label>
    <description>all the participants in this group will be performed with intracranial stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intracranial stenting</intervention_name>
    <description>all the participants in this group will be performed with intracranial stenting</description>
    <arm_group_label>Intracranial stenting group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This trial is an prospective, government-funded registration study that will observe the
        safety and effectiveness of intracranial stenting for preventing stroke during a mean
        follow-up of 3 years in patients with symptomatic stenosis of a major intracranial artery
        (MCA, carotid, vertebral, basilar). This trial was launched by Xuanwu Hospital, Capital
        University of Medical Science, with 20 collaborators participating. Enrollment will begin
        in 2013, and it aims to have a sample size of 840 subjects in 2 years. The trial is
        scheduled to complete in 2015.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic status: as evidenced by TIA or non-severe stroke within the past 12 months
             attributed to 70% to 99% stenosis of a major intracranial artery (carotid artery, MCA
             stem [M1], vertebral artery, or basilar artery).

          -  Degree of stenosis: 70%-99%; (Stenosis must be confirmed by catheter angiography for
             enrollment in the trial,WASID method)

          -  Age:30-80 years;

          -  No fresh infarctions identified on MRI (indicated as high signals on DWI series) upon
             enrollment

          -  No massive cerebral infarction (&gt;1/2 MCA territory), intracranial hemorrhage, epidural
             or sub-dural hemorrhage, and intracranial brain tumor on CT or MRI scan

          -  mRS scale score of &lt;=2

          -  Target vessel reference diameter must be measure d to be 2.00 mm to 4.50 mm; target
             area of stenosis is &lt;=14 mm in length

          -  Patient is willing and able to return for all follow-up visits required by the
             protocol

          -  Patient understands the purpose and requirements of the study, can make him/herself
             understood, and has signed informed consent.

        Exclusion Criteria:

          -  Untoward reaction to anesthesia.

          -  Any condition that precludes proper angiographic assessment or makes percutaneous
             arterial access unsafe.

          -  Tandem extracranial or intracranial stenosis that is proximal or distal to the target
             intracranial lesion

          -  Previous treatment of target lesion with a stent, angioplasty, or other mechanical
             device.

          -  Any aneurysm proximal to or distal to stenotic intracranial artery. Intracranial tumor
             (except meningioma) or any intracranial vascular malformation

          -  Computed tomographic or angiographic evidence of severe calcification at target lesion

          -  Stroke of sufficient size (&gt;5cm on CT or MRI) to place patient at risk of hemorrhagic
             conversion during the procedure.Hemorrhagic transformation of an ischemic stroke
             within the past 15 days.

          -  Previous spontaneous intracerebral (parenchymal) or other intracranial (subarachnoid,
             subdural, or epidural) hemorrhage within 30 days

          -  Untreated chronic subdural hematoma &gt;5 mm in thickness

          -  Intracranial arterial stenosis related to arterial dissection, moya-moya disease or
             any known vasculitic disease;

          -  MI within previous 30 days

          -  Any episode of paroxysmal atrial fibrillation within the past 6 months, or history of
             paroxysmal atrial fibrillation requiring chronic anticoagulation

          -  Intolerance or allergic reaction to any of the study medications, including aspirin,
             clopidogrel, heparin, nitinol, and local or general anaesthesia History of
             life-threatening allergy to contrast dye. If not life-threatening and can be
             effectively pretreated, patient can be enrolled at physicians discretion

          -  Recent GI bleed that would interfere with antiplatelet therapy. Active bleeding
             diathesis or coagulopathy; active peptic ulcer disease, major systemic hemorrhage
             within 30 days, active bleeding diathesis, platelets count &lt;125,000, hematocrit &lt;30,
             Hgb &lt;10 g/dl, uncorrected INR &gt;1.5, bleeding time &gt;1 minute beyond upper limit normal,
             or heparin-associated thrombocytopenia that increases the risk of bleeding,
             uncontrolled severe hypertension (systolic BP&gt;180 mm hg or diastolic BP&gt;115 mm hg),
             severe liver impairment (AST or ALT &gt;3 times normal, cirrhosis), creatinine
             &gt;265.2Î¼mol/l (unless on dialysis)

          -  Major surgery (including open femoral, aortic, or carotid surgery) within previous 30
             days or planned in the next 90 days after enrollment

          -  Severe dementia or psychiatric problem that prevents the patient from following an
             outpatient program reliably

          -  Pregnancy or of childbearing potential and unwilling to use contraception for the
             duration of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Ling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Capital University of Medical Sciences, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liqun Jiao, MD</last_name>
    <phone>86-10-83198899</phone>
    <phone_ext>8836</phone_ext>
    <email>jiaoliqun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yabing Wang, MD</last_name>
    <phone>86-10-83198990</phone>
    <email>wangyabing@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of neurosurgery, Xuanwu hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liqun Jiao, MD</last_name>
      <phone>86-10-83198899</phone>
      <phone_ext>8836</phone_ext>
      <email>jiaoliqun@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7. Erratum in: N Engl J Med. 2012 Jul 5;367(1):93.</citation>
    <PMID>21899409</PMID>
  </results_reference>
  <results_reference>
    <citation>Feigin VL. Stroke epidemiology in the developing world. Lancet. 2005 Jun 25-Jul 1;365(9478):2160-1.</citation>
    <PMID>15978910</PMID>
  </results_reference>
  <results_reference>
    <citation>Zaidat OO, Klucznik R, Alexander MJ, Chaloupka J, Lutsep H, Barnwell S, Mawad M, Lane B, Lynn MJ, Chimowitz M; NIH Multi-center Wingspan Intracranial Stent Registry Study Group. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology. 2008 Apr 22;70(17):1518-24. doi: 10.1212/01.wnl.0000306308.08229.a3. Epub 2008 Jan 30.</citation>
    <PMID>18235078</PMID>
  </results_reference>
  <results_reference>
    <citation>Fiorella D, Levy EI, Turk AS, Albuquerque FC, Niemann DB, Aagaard-Kienitz B, Hanel RA, Woo H, Rasmussen PA, Hopkins LN, Masaryk TJ, McDougall CG. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke. 2007 Mar;38(3):881-7. Epub 2007 Feb 8.</citation>
    <PMID>17290030</PMID>
  </results_reference>
  <results_reference>
    <citation>Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 Mar 31;352(13):1305-16.</citation>
    <PMID>15800226</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>intracranial stenting</keyword>
  <keyword>vascular risk factor management</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

